VYYRF (Voyageur Pharmaceuticals) Research & Development: $0.83 Mil (TTM As of Feb. 2026)


VYYRF Voyageur Pharmaceuticals Ltd VYYRF
18 GF Score
Price $0.10
! 5 Warning Signs
View Full Analysis

What is Voyageur Pharmaceuticals Research & Development?

Voyageur Pharmaceuticals VYYRF +7.71% 18 Research & Development is $0.83 Mil as of Feb. 2026. GuruFocus rates VYYRF with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Voyageur Pharmaceuticals's Research & Development for the three months ended in Feb. 2026 was $0.21 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 was $0.83 Mil.

Voyageur Pharmaceuticals  (OTCPK:VYYRF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Voyageur Pharmaceuticals Research & Development Related Terms

Voyageur Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Voyageur Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyageur Pharmaceuticals Research & Development Chart

Voyageur Pharmaceuticals Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 0.39 0.21 0.21 0.65

Voyageur Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.04 0.38 0.20 0.21
VYYRF
18GF Score
Voyageur Pharmaceuticals Ltd VYYRF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyageur Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.83 Mil mean?
Voyageur Pharmaceuticals (VYYRF) has a Research & Development of $0.83 Mil as of Feb. 2026. Research and development expense is the total cost for research and development activities. View historical data on Voyageur Pharmaceuticals and its competitors.
Is Voyageur Pharmaceuticals' Research & Development too high?
Voyageur Pharmaceuticals' current Research & Development is $0.83 Mil. Overall, Voyageur Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' Research & Development compare to ZTS and UTHR?
Voyageur Pharmaceuticals' Research & Development of $0.83 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Voyageur Pharmaceuticals and its competitors. Voyageur Pharmaceuticals's current Research & Development is $0.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current Research & Development of $0.83 Mil. The current Research & Development is $0.83 Mil. Voyageur Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current Research & Development is $0.83 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Voyageur Pharmaceuticals Business Description

Other Exchanges VM:Canada
Address 4103B Center Street NW, Calgary, AB, CAN, T2E 2Y6
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
18GF Score

Get the complete analysis for VYYRF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price